# Daily Todo List

**Date:** 1-22-2026

MESSAGE: You are the head assistant for Glassbox Bio - . You coordinate multiple specialized workflows and report status to Wes.\n\n Available workflows:\n - content_creation: Generate marketing content\n - crm_enrichment: Update CRM with new contact data\n   - daily_briefing: Compile overnight activity \n When Wes requests something:\n 1. Determine if a pre-built workflow exists\n 2. Trigger the workflow via MCP tool\n 3. Monitor its progress\n 4. Report back to Wes with results\n For tasks requiring approval, use the request_approval MCP tool.\n  COMPANY INFORMATION CONTEXT: Independent validation for AI drug discovery ‚Äî delivered in 72 hours.\n\nReproducible, evidence-linked target diligence for founders, investors, and diligence teams.\nWhat Glassbox Bio is\n\nGlassbox Bio is a pure-service, independent diligence company building an audit-grade validation layer for early drug programs. We turn "plausible" AI outputs into decision-grade conclusions by enforcing:\n Evidence-linked claims (each high-impact claim maps to inspectable sources)\n    Admissibility gates that surface missing evidence and contradictions instead of smoothing them over\n    Reproducibility artifacts (run records, structured outputs, and reviewable methods)\n\nOur reports are designed to be defensible in investor and board contexts, not merely persuasive. Why now\n\nAI increased the number of hypotheses teams can generate. It did not increase the number of verifiable decisions teams can defend. In biotech, verification is expensive and mistakes compound‚Äîso diligence needs to be structured, reproducible, and evidence-bound.\nOur independence promise\n\nWe have no internal pipeline and do not take positions that compromise neutrality. We exist to audit biology and supporting claims‚Äîfast, traceably, and reproducibly


NOTE: YOUR DESIGNATED GLASSBOX-OPERATOR MCP SERVER INSTRUCTIONS is located in the file "./MCP_OPERATOR_USAGE.md" in the root directory. 

## üìù Process Instructions
1.  **Start of Day:**
    *   Archive the previous day's content if it hasn't been done: `mv DAILY_TODO.md daily_todos/$(date -d "yesterday" +%Y-%m-%d).md` (or manually move and rename).
    *   Update the **Date** field above.
    *   Review pending tasks from the previous day and migrate them here if still relevant.
2.  **During the Day:**
    *   Mark completed tasks on here as historical. Everytime you complete a task, always sign off on the task included the date and exact time completed. 

    *   Check off items as they are completed: `- [x] Task Name`
    *   Add new tasks as they arise.
3.  **End of Day:**
    *   Ensure the file is saved in the "daily_todos" directory in the following format "<date>_DAILY_TODO.md"
    *   (Optional) Prepare the archive move for the next morning.

## üöÄ Tasks for Today

- [ ] Check system health (Operator Status)
- [ ] Review recent alerts or logs
- [ ] Update documentation if needed
- [ ] (Add specific tasks here)
- [ ] Review Blog Draft: Weekly AI Biotech Roundup (See below)

### üìÑ Blog Draft: The Bio-AI Pulse (Jan 17-23, 2026)

**Executive Summary**
This week marked a definitive shift from "AI experimentation" to "AI infrastructure." The headline isn't just about money‚Äîit's about integration. With Eli Lilly and NVIDIA dropping $1B on a co-innovation lab, and a swarm of platform-focused deals (Chai, Boltz, Noetik), Big Pharma is signaling that they are done dipping their toes in. They are buying the pool. For founders and VCs, the message is clear: The value premium is moving from single-asset AI discoveries to scalable, multi-target generation platforms.

**1. The Headline: Lilly & NVIDIA‚Äôs $1B "Lab in the Loop"**
*The Deal:* A five-year, $1 billion partnership to build a co-located AI lab in the Bay Area.
*The Why:* This isn't a vendor contract; it's a merger of cultures. By colocating pharma scientists with NVIDIA's AI engineers, they aim to break the silo between "computational" and "wet" labs.
*Implication:* Expect BioNeMo models to become the de facto standard infrastructure for target-to-candidate decision-making.

**2. Deal Flow: The Platform Premium**
We saw a flurry of deals emphasizing *breadth* over depth:
*   **Chai Discovery x Eli Lilly:** Leveraging the Chai-2 model for multi-target biologics, specifically targeting undruggable GPCRs. (Chai is fresh off a $130M Series B).
*   **Boltz x Pfizer:** A custom model play for small molecules and biologics.
*   **Noetik x GSK:** Cancer prediction modeling.
*   **Isomorphic Labs x J&J:** A third major pharma deal for the DeepMind spinout, cementing the "AI-as-Service" model.
*VC Takeaway:* Big Pharma is hungry for engines, not just eggs. Ventures that can demonstrate a repeatable, high-fidelity generation platform are capturing the largest checks.

**3. Clinical Validation: Insilico Strikes Again**
*The News:* Insilico Medicine received FDA IND approval for **ISM8969**, an oral candidate for fibrosis.
*The Stat:* Developed in 12-18 months (vs. the industry standard of 4.5 years).
*Why it Matters:* Speed is the ultimate ROI in biotech. Insilico continues to provide the empirical evidence that AI doesn't just design "cool" molecules‚Äîit designs clinically viable ones, faster.

**4. M&A: AstraZeneca Buys Capabilities**
AstraZeneca acquired **Modella AI**, a specialist in multimodal oncology modeling. This move to bring AI in-house (integrating pathology, molecular, and clinical data) highlights the buy-vs-build tension. Expect more acqui-hires of specialized AI teams as big pharma races to modernize their R&D stacks.

## üìå Backlog / Notes
*   
